December 1962

Iproniazid in Healing of Chronic Topical Ulcers

Author Affiliations

Resident, Surgical Service, Veterans Administration Hospital (Dr. Goldstein); Chief, Surgical Service, Veterans Administration Hospital, and Associate Professor of Surgery, University of Miami School of Medicine (Dr. Wolcott); Consultant, Medical Service, Veterans Administration Hospital (Dr. Rosenstein).

Arch Surg. 1962;85(6):1011-1015. doi:10.1001/archsurg.1962.01310060147026

The treatment of chronic topical ulcerations has long been a problem to medical practitioners. Hippocrates recorded ulcers of the leg among his patients. Ochsner and Mahorner7 and Steubner14 report that varicose ulcers were present in 28% and 49% respectively of surgical cases of varicose veins. Other types of chronic ulcerations such as decubitus, arterial, and traumatic ulcers have likewise presented a continuing challenge to the physician.

The purpose of this investigation was to evaluate another modality for the treatment of chronic ulcerations. We included in this study only those ulcers which had failed to show an adequate response to the classical methods of therapy.

Iproniazid,* a chemical derivative of isoniazid, was first introduced in 1951 as an antituberculosis drug. On several occasions Bosworth1,2 has described its efficacy in promoting healing in bone and joint tuberculosis. He also states that when iproniazid was used orally in acute osteomyelitic

First Page Preview View Large
First page PDF preview
First page PDF preview